Dendreon to raise up to $448 million to fund Provenge commercialisation
This article was originally published in Scrip
Executive Summary
Dendreon is launching a sale of its common stock in which it expects to raise about $389 million, rising to $448 million if the underwriters' over-allotment option is exercised in full. The actual amount raised will depend on the offer price, which has not yet been officially determined.